New pill shows promise for rare blood disorder PNH in early trial
NCT ID NCT06764303
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times
Summary
This Phase 2 trial tests an experimental oral drug called NTQ5082 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down. The study involves 24 adults who have not previously received complement inhibitor therapy. The main goal is to see if the drug can raise hemoglobin levels by at least 20 g/L and reduce the need for blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 250033, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310012, China
Conditions
Explore the condition pages connected to this study.